查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球小儿神经科设备市场 - 2023-2030
市场调查报告书
商品编码
1374888

全球小儿神经科设备市场 - 2023-2030

Global Pediatric Neurology Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

小儿神经病学是治疗的一个专门组成部分，涉及新生儿、婴儿、青少年和青少年神经系统疾病的检测和管理。儿科神经科设备是用来解决青少年神经系统问题的仪器。儿科神经科设备中采用的技术是为治疗神经系统疾病而开发的。

市场动态：驱动因素与限制因素

产品介绍的增加

儿科神经设备进入市场的增加预计将在预测期内推动全球市场的成长。例如，2023 年7 月，尼克劳斯儿童医院推出了新型高密度脑电图(HD EEG) 系统和经颅磁刺激(TMS) 机，成为美国最先进的为儿科患者提供此类设备的医院之一。

此外，2022年10月，NeuroSigma推出了用于治疗儿科注意力不足/过动症（ADHD）的Monarch eTNS系统和儿科护理共付额计划，以促进患者获得此开发成果。此外，不断增长的技术进步、不断提高的意识和案例等因素预计也将有助于预测期内全球市场的成长。

设备成本高

神经科设备的高成本预计将阻碍预测期内的全球市场成长。例如，迷走神经刺激（VNS）疗法是治疗难治性癫痫患者的既定方法，而该设备的初始成本约为10,000美元，这又需要定期更换电池，增加了总体成本，减缓了全球市场的成长。此外，缺乏专业专家和高昂的产品开发成本等其他因素正在减缓预测期内的全球市场成长。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按产品类型分類的片段
  • 按指示显示的片段
  • 按年龄组别分類的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 产品介绍的增加
    • 限制
      • 设备成本高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 报销分析
  • 专利分析
  • 科技趋势
  • 流行病学
  • SWOT分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按产品类型

  • 神经刺激装置
  • 神经外科设备
  • 介入性器械
  • CSF 管理设备
  • 其他产品类型

第 8 章：依指示

  • 癫痫
  • 中风
  • 脑积水
  • 神经肿瘤学适应症
  • 其他适应症

第 9 章：按年龄组

  • 0-5岁
  • 5-10年
  • 10-15岁

第 10 章：最终用户

  • 医院
  • 专科诊所
  • 门诊手术中心 (ASC)
  • 其他的

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Abbott Laboratories
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • LivaNova PLC
  • Medtronic PLC, Inc.
  • Natus Medical Inc.
  • Stryker Corporation
  • B.Barun SE
  • Integra LifeSciences Corporation, Inc.
  • Boston Scientific Corporation
  • NeuroSigma, Inc.
  • Zimmer Biomet

第 14 章：附录

简介目录
Product Code: MD7189

Overview

Pediatric neurology is addressed as a specialized component of treatment that deals with the detection and management of neurological disorders in neonates (newborns), infants, juveniles, and adolescents. Pediatric neurology devices are the instruments that are utilized to address neurological issues in youngsters. The technology employed in pediatric neurology devices is developed for curing neurological conditions.

Market Dynamics: Drivers & Restraints

Increase in Product Introductions

The increase in pediatric neurological device introductions into the market is expected to boost the global market growth during the forecast period. For instance, in July 2023, Nicklaus Children's Hospital introduced a new high-density electroencephalogram (HD EEG) system and transcranial magnetic stimulation (TMS) machine, evolving as one of the foremost in the country to deliver this equipment for the care of pediatric individuals.

Moreover, in October 2022, NeuroSigma introduced the Monarch eTNS System for treating pediatric attention-deficit/hyperactivity disorder (ADHD) and the Pediatric Care Copay program to promote patient access to the development. Furthermore, growing technological advancements, growing awareness and cases among other factors are also expected to contribute to the global market growth during the forecast period.

High Device Cost

The high cost of neurology devices is expected to hamper the global market growth during the forecast period. For instance, Vagus nerve stimulation (VNS) therapy is an established method for treating patients with refractory seizures, while the initial cost of the device is about 10,000 US dollars which again requires regular battery changes adding to the overall cost, slowing the global market growth. Furthermore, the lack of professional specialists and high product development costs among other additional factors are slowing the global market growth in the forecast period.

Segment Analysis

The global pediatric neurology devices market is segmented based on product type, indication, age group, end user and region.

Nerve Simulation Product Type is Expected to Dominate Market

Owing to the increase in new product introductions into the segment the nerve simulation product type is expected to hold the majority of the global market share during the forecast period. For instance, in February 2021, the FDA awarded 510(k) authorization to electroCore to extend the authorization of gammaCore, the corporation's non-invasive vagus nerve stimulation, for the acute and preventative therapy of adolescent migraine. Moreover, in February 2023, LivaNova PLC, a top medical technology and innovation corporation, introduced SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to deliver VNS Therapy in the treatment of drug-resistant epilepsy.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the increase in pediatric neurology device market developments in North America the region is expected to dominate the global market during the forecast period. For instance, in October 2022, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation, introduced the Monarch eTNS System the foremost medical device authorized by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD for pediatric patients (i.e., children ages 7-12), at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.

Also, in December 2022, Brain Scientific, a Florida-based applied science technology corporation, formed a new distribution agreement with MVAP Medical Supplies to push sales into the rapidly expanding and underserved pediatric EEG marketplace.

Further, in January 2023, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation trading external trigeminal nerve stimulation (eTNS) technology for the treatment of neurological and neuropsychiatric disorders, began a strategic digital marketing collaboration with Data360, a top provider of targeted, online marketing for the healthcare industry.

COVID-19 Impact Analysis

Various neurological manifestations have been associated with children's SARS-CoV-2 infection. It was crucial to identify and provide them with appropriate and timely treatment because they can be potentially serious and life-threatening, and some can lead to long-lasting consequences.

Different neuro-pathophysiological mechanisms were presented, but a causal relationship between SARS-CoV-2 infection and neurological manifestations stays unproven. COVID-19 affects patients with neurological diseases especially, not only by the disease itself but also by its complications and pandemic management measures, which has impacted the gbal market in a mixed way.

Market Segmentation

By Product Type

  • Neurostimulation Devices
  • Neurosurgery Devices
  • Interventional Devices
  • CSF Management Devices
  • Other Product Types

By Indication

  • Seizure
  • Stroke
  • Hydrocephalus
  • Neurooncological Indications
  • Other Indications

By Age Group

  • 0-5 Years
  • 5-10 Years
  • 10-15 Years

By End User

  • Hospital
  • Specialty Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In June 2023, Biogen Inc. launched a new SPINRAZA (nusinersen) data strived to answer critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA.
  • In October 2022, Axoft, a neurotechnology corporation, introduced and obtained the FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders.
  • In October 2022, SpineX, Inc., a clinical-stage medtech corporation reported the groundbreaking results of its first in-human study in children with cerebral palsy.
  • In January 2021, Theranica, a prescribed digital therapeutics (PDT) corporation obtained the Food and Drug Administration clearance to market its Nerivio therapeutic device for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, LivaNova PLC, Medtronic PLC, Natus Medical Inc., Stryker Corporation, B.Barun SE, Integra Lifesciences Corporation, Boston Scientific Corporation, Zimmer Biomet and NeuroSigma, Inc. among others.

Why Purchase the Report?

  • To visualize the global pediatric neurology devices market segmentation based on product type, indication, age group, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pediatric neurology devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pediatric neurology devices market report would provide approximately 69 tables, 73 figures and 194 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in Product Introductions
    • 4.1.2. Restraints
      • 4.1.2.1. High Device Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. Technology Trend
  • 5.8. Epidemiology
  • 5.9. SWOT Analysis
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Neurostimulation Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Neurosurgery Devices
  • 7.4. Interventional Devices
  • 7.5. CSF Management Devices
  • 7.6. Other Product Types

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Seizure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Stroke
  • 8.4. Hydrocephalus
  • 8.5. Neurooncological Indications
  • 8.6. Other Indications

9. By Age Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.1.2. Market Attractiveness Index, By Age Group
  • 9.2. 0-5 Years*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. 5-10 Years
  • 9.4. 10-15 Years

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers (ASCs)
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. LivaNova PLC
  • 13.3. Medtronic PLC, Inc.
  • 13.4. Natus Medical Inc.
  • 13.5. Stryker Corporation
  • 13.6. B.Barun SE
  • 13.7. Integra LifeSciences Corporation, Inc.
  • 13.8. Boston Scientific Corporation
  • 13.9. NeuroSigma, Inc.
  • 13.10. Zimmer Biomet

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us